{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:13:43Z","timestamp":1740107623805,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00467-020-04652-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T04:12:41Z","timestamp":1591935161000},"page":"1365-1375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-4531","authenticated-orcid":false,"given":"Franca","family":"Iorember","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"4652_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nrneph.2009.28","volume":"5","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 5:186\u2013188. https:\/\/doi.org\/10.1038\/nrneph.2009.28","journal-title":"Nat Rev Nephrol"},{"key":"4652_CR2","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687. https:\/\/doi.org\/10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"issue":"5","key":"4652_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","volume":"92","author":"V Brocklebank","year":"2017","unstructured":"Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92(5):1261\u20131271. https:\/\/doi.org\/10.1016\/j.kint.2017.04.028","journal-title":"Kidney Int"},{"key":"4652_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A, Indian HUS Registry (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160. https:\/\/doi.org\/10.1038\/ki.2013.373","journal-title":"Kidney Int"},{"key":"4652_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS\/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267\u20131279. https:\/\/doi.org\/10.1182\/blood-2005-10-007252","journal-title":"Blood"},{"key":"4652_CR6","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"112","author":"V Fr\u00e9meaux-Bacchi","year":"2008","unstructured":"Fr\u00e9meaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112:4948\u20134952. https:\/\/doi.org\/10.1182\/blood-2008-01-133702","journal-title":"Blood"},{"key":"4652_CR7","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","volume":"23","author":"C Loirat","year":"2008","unstructured":"Loirat C, Noris M, Fremeaux-Bacchi V (2008) Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23:1957\u20131972. https:\/\/doi.org\/10.1007\/s00467-008-0872-4","journal-title":"Pediatr Nephrol"},{"key":"4652_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","volume":"27","author":"LM Geerdink","year":"2012","unstructured":"Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, K\u00f6mhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283\u20131291. https:\/\/doi.org\/10.1007\/s00467-012-2131-y","journal-title":"Pediatr Nephrol"},{"key":"4652_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361:345\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa0810739","journal-title":"N Engl J Med"},{"key":"4652_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ndt\/gfp388","volume":"25","author":"S Strobel","year":"2010","unstructured":"Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, J\u00f3zsi M (2010) Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 25:136\u2013144. https:\/\/doi.org\/10.1093\/ndt\/gfp388","journal-title":"Nephrol Dial Transplant"},{"key":"4652_CR11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","volume":"10","author":"M Puraswani","year":"2019","unstructured":"Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol 10:1282. https:\/\/doi.org\/10.3389\/fimmu.2019.01282","journal-title":"Front Immunol"},{"key":"4652_CR12","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.smim.2019.101341","volume":"45","author":"M Cserhalmi","year":"2019","unstructured":"Cserhalmi M, Papp A, Brandus B, Uzonyi B, J\u00f3zsi M (2019) Regulation of regulators: role of the complement factor H-related proteins. Semin Immunol 45:101341. https:\/\/doi.org\/10.1016\/j.smim.2019.101341","journal-title":"Semin Immunol"},{"key":"4652_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2009.07.005","volume":"126","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF (2009) Complement and immune defense: from innate immunity to human diseases. Immunol Lett 126:1\u20137. https:\/\/doi.org\/10.1016\/j.imlet.2009.07.005","journal-title":"Immunol Lett"},{"key":"4652_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","volume":"56","author":"C Skerka","year":"2013","unstructured":"Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT (2013) Complement factor H related proteins (CFHRs). Mol Immunol 56:170\u2013180. https:\/\/doi.org\/10.1016\/j.molimm.2013.06.001","journal-title":"Mol Immunol"},{"key":"4652_CR15","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1074\/jbc.272.9.5627","volume":"272","author":"C Skerka","year":"1997","unstructured":"Skerka C, Hellwage J, Weber W, Tilkorn A, Buck F, Marti T, Kampen E, Beisiegel U, Zipfel PF (1997) The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins. J Biol Chem 272:5627\u20135634. https:\/\/doi.org\/10.1074\/jbc.272.9.5627","journal-title":"J Biol Chem"},{"key":"4652_CR16","doi-asserted-by":"publisher","first-page":"12015","DOI":"10.1016\/S0021-9258(18)99058-7","volume":"266","author":"C Skerka","year":"1991","unstructured":"Skerka C, Horstmann RD, Zipfel PF (1991) Molecular cloning of a human serum protein structurally related to complement factor H. J Biol Chem 266:12015\u201312020","journal-title":"J Biol Chem"},{"key":"4652_CR17","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/S0021-9258(18)53859-X","volume":"268","author":"C Skerka","year":"1993","unstructured":"Skerka C, K\u00fchn S, G\u00fcnther K, Lingelbach K, Zipfel PF (1993) A novel short consensus repeat-containing molecule is related to human complement factor H. J Biol Chem 268:2904\u20132908","journal-title":"J Biol Chem"},{"issue":"Suppl 8","key":"4652_CR18","doi-asserted-by":"publisher","first-page":"I9","DOI":"10.1016\/j.vaccine.2008.11.021","volume":"26","author":"C Skerka","year":"2008","unstructured":"Skerka C, Zipfel PF (2008) Complement factor H related proteins in immune diseases. Vaccine 26(Suppl 8):I9\u2013I14. https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.021","journal-title":"Vaccine"},{"key":"4652_CR19","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","volume":"114","author":"C Abarrategui-Garrido","year":"2009","unstructured":"Abarrategui-Garrido C, Mart\u00ednez-Barricarte R, L\u00f3pez-Trascasa M, de C\u00f3rdoba SR, S\u00e1nchez-Corral P (2009) Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114:4261\u20134271. https:\/\/doi.org\/10.1182\/blood-2009-05-223834","journal-title":"Blood"},{"key":"4652_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1055\/s-0030-1262885","volume":"36","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB (2010) Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 36:633\u2013640. https:\/\/doi.org\/10.1055\/s-0030-1262885","journal-title":"Semin Thromb Hemost"},{"key":"4652_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.4049\/jimmunol.1600053","volume":"197","author":"D Buhlmann","year":"2016","unstructured":"Buhlmann D, Eberhardt HU, Medyukhina A, Prodinger WM, Figge MT, Zipfel PF, Skerka C (2016) FHR3 blocks C3d-mediated coactivation of human B cells. J Immunol 197:620\u2013629. https:\/\/doi.org\/10.4049\/jimmunol.1600053","journal-title":"J Immunol"},{"key":"4652_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/s-0030-1262884","volume":"36","author":"C Skerka","year":"2010","unstructured":"Skerka C, Zipfel PF, M\u00fcller D, Micklisch S, Riedl M, Zimmerhackl LB, Hofer J (2010) The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost 36:625\u2013632. https:\/\/doi.org\/10.1055\/s-0030-1262884","journal-title":"Semin Thromb Hemost"},{"key":"4652_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jca.21276","volume":"28","author":"J Schwartz","year":"2013","unstructured":"Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH (2013) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145\u2013284. https:\/\/doi.org\/10.1002\/jca.21276","journal-title":"J Clin Apher"},{"key":"4652_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00467-014-2948-7","volume":"30","author":"P Khandelwal","year":"2015","unstructured":"Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A (2015) Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30:451\u2013457. https:\/\/doi.org\/10.1007\/s00467-014-2948-7","journal-title":"Pediatr Nephrol"},{"key":"4652_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","volume":"55","author":"O Boyer","year":"2010","unstructured":"Boyer O, Balzamo E, Charbit M, Biebuyck-Goug\u00e9 N, Salomon R, Dragon-Durey MA, Fr\u00e9meaux-Bacchi V, Niaudet P (2010) Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 55:923\u2013927. https:\/\/doi.org\/10.1053\/j.ajkd.2009.12.026","journal-title":"Am J Kidney Dis"},{"key":"4652_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5414\/CN107777","volume":"83","author":"JJ Kim","year":"2015","unstructured":"Kim JJ, McCulloch M, Marks SD, Waters A, Noone D (2015) The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin Nephrol 83:49\u201356. https:\/\/doi.org\/10.5414\/CN107777","journal-title":"Clin Nephrol"},{"key":"4652_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molimm.2015.12.005","volume":"70","author":"P Nozal","year":"2016","unstructured":"Nozal P, Bernab\u00e9u-Herrero ME, Uzonyi B, Szil\u00e1gyi \u00c1, Hyv\u00e4rinen S, Proh\u00e1szka Z, Jokiranta TS, S\u00e1nchez-Corral P, L\u00f3pez-Trascasa M, J\u00f3zsi M (2016) Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Mol Immunol 70:47\u201355. https:\/\/doi.org\/10.1016\/j.molimm.2015.12.005","journal-title":"Mol Immunol"},{"key":"4652_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","volume":"32","author":"A Hackl","year":"2017","unstructured":"Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S (2017) Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol 32:1081\u20131087. https:\/\/doi.org\/10.1007\/s00467-017-3612-9","journal-title":"Pediatr Nephrol"},{"key":"4652_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/08916930903019119","volume":"42","author":"MC Salinas-Carmona","year":"2009","unstructured":"Salinas-Carmona MC, Perez LI, Galan K, Vazquez AV (2009) Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB\/c mice. Autoimmunity 42:537\u2013544. https:\/\/doi.org\/10.1080\/08916930903019119","journal-title":"Autoimmunity"},{"key":"4652_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ (2010) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379\u2013387. https:\/\/doi.org\/10.1182\/blood-2009-05-221549","journal-title":"Blood"},{"key":"4652_CR31","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","volume":"23","author":"T Kwon","year":"2008","unstructured":"Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, Fremeaux-Bacchi V, Loirat C (2008) Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 23:2088\u20132090. https:\/\/doi.org\/10.1093\/ndt\/gfn063","journal-title":"Nephrol Dial Transplant"},{"key":"4652_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","volume":"12","author":"MA Durey","year":"2016","unstructured":"Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563\u2013578. https:\/\/doi.org\/10.1038\/nrneph.2016.99","journal-title":"Nat Rev Nephrol"},{"key":"4652_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","volume":"29","author":"G Sana","year":"2014","unstructured":"Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvi\u00e8re C, B\u00e9rard E, Salomon R, Fr\u00e9meaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29:75\u201383. https:\/\/doi.org\/10.1007\/s00467-013-2558-9","journal-title":"Pediatr Nephrol"},{"key":"4652_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fr\u00e9meaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"4652_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","volume":"221","author":"BP Morgan","year":"2016","unstructured":"Morgan BP (2016) The membrane attack complex as an inflammatory trigger. Immunobiology 221:747\u2013751. https:\/\/doi.org\/10.1016\/j.imbio.2015.04.006","journal-title":"Immunobiology"},{"key":"4652_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.molimm.2016.07.016","volume":"77","author":"G Brachet","year":"2016","unstructured":"Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-Gruart V, Poupon A, Watier H (2016) Eculizumab epitope on complement C5: progress towards a better understanding of the mechanism of action. Mol Immunol 77:126\u2013131. https:\/\/doi.org\/10.1016\/j.molimm.2016.07.016","journal-title":"Mol Immunol"},{"key":"4652_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Br\u00fcggemann RJ (2019) Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 58:859\u2013874. https:\/\/doi.org\/10.1007\/s40262-019-00742-8","journal-title":"Clin Pharmacokinet"},{"key":"4652_CR38","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"4652_CR39","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) Eculizumab safety: five-year experience from the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 4:1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"},{"key":"4652_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","volume":"80","author":"PE Crew","year":"2020","unstructured":"Crew PE, McNamara L, Waldron PE, McCulley L, Christopher Jones S, Bersoff-Matcha SJ (2020) Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Inf Secur 80:350\u2013371. https:\/\/doi.org\/10.1016\/j.jinf.2019.11.015","journal-title":"J Inf Secur"},{"issue":"27","key":"4652_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR (2017) High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep 66(27):734\u2013737. https:\/\/doi.org\/10.15585\/mmwr.mm6627e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4652_CR42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C (2014) Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29:841\u2013851. https:\/\/doi.org\/10.1007\/s00467-013-2654-x","journal-title":"Pediatr Nephrol"},{"key":"4652_CR43","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","volume":"133","author":"B Diamante Chiodini","year":"2014","unstructured":"Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B (2014) Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 133:e1764\u2013e1768. https:\/\/doi.org\/10.1542\/peds.2013-1594","journal-title":"Pediatrics"},{"key":"4652_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.transproceed.2016.11.008","volume":"49","author":"P Dedhia","year":"2017","unstructured":"Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG (2017) Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report. Transplant Proc 49:188\u2013192. https:\/\/doi.org\/10.1016\/j.transproceed.2016.11.008","journal-title":"Transplant Proc"},{"key":"4652_CR45","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fpls.2019.00260","volume":"10","author":"O Top","year":"2019","unstructured":"Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, H\u00e4ffner K, Reski R, Decker EL (2019) Recombinant production of MFHR1, a novel synthetic multitarget complement inhibitor, in moss bioreactors. Front Plant Sci 10:260. https:\/\/doi.org\/10.3389\/fpls.2019.00260","journal-title":"Front Plant Sci"},{"key":"4652_CR46","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1681\/ASN.2017070738","volume":"29","author":"S Michelfelder","year":"2018","unstructured":"Michelfelder S, Fischer F, W\u00e4ldin A, H\u00f6rle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, H\u00e4ffner K (2018) The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential. J Am Soc Nephrol 29:1141\u20131153. https:\/\/doi.org\/10.1681\/ASN.2017070738","journal-title":"J Am Soc Nephrol"},{"key":"4652_CR47","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","volume":"221","author":"Z Proh\u00e1szka","year":"2016","unstructured":"Proh\u00e1szka Z, Nilsson B, Frazer-Abel A, Kirschfink M (2016) Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology 221:1247\u20131258. https:\/\/doi.org\/10.1016\/j.imbio.2016.06.008","journal-title":"Immunobiology"},{"key":"4652_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/15321819.2019.1696819","volume":"41","author":"KE Kerboua","year":"2020","unstructured":"Kerboua KE, Djenouhat K (2020) Semi-solid phase assay for the alternative complement pathway activity assessment (AP100). J Immunoassay Immunochem 41:144\u2013151. https:\/\/doi.org\/10.1080\/15321819.2019.1696819","journal-title":"J Immunoassay Immunochem"},{"key":"4652_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/CDLI.6.1.137-139.1999","volume":"6","author":"TD Jaskowski","year":"1999","unstructured":"Jaskowski TD, Martins TB, Litwin CM, Hill HR (1999) Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol 6:137\u2013139","journal-title":"Clin Diagn Lab Immunol"},{"key":"4652_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","volume":"183","author":"B Puissant-Lubrano","year":"2017","unstructured":"Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A (2017) Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clin Immunol 183:1\u20137. https:\/\/doi.org\/10.1016\/j.clim.2017.06.007","journal-title":"Clin Immunol"},{"key":"4652_CR51","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3791\/1923","volume":"37","author":"M Costabile","year":"2010","unstructured":"Costabile M (2010) Measuring the 50% haemolytic complement (CH50) activity of serum. J Vis Exp 37:1923. https:\/\/doi.org\/10.3791\/1923","journal-title":"J Vis Exp"},{"key":"4652_CR52","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1128\/cdli.10.6.982-989.2003","volume":"10","author":"M Kirschfink","year":"2003","unstructured":"Kirschfink M, Mollnes TE (2003) Modern complement analysis. Clin Diagn Lab Immunol 10:982\u2013989. https:\/\/doi.org\/10.1128\/cdli.10.6.982-989.2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"4652_CR53","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/ajh.24209","volume":"90","author":"AR Shih","year":"2015","unstructured":"Shih AR, Murali MR (2015) Laboratory tests for disorders of complement and complement regulatory proteins. Am J Hematol 90:1180\u20131186. https:\/\/doi.org\/10.1002\/ajh.24209","journal-title":"Am J Hematol"},{"key":"4652_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI (2009) Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res 66:336\u2013340. https:\/\/doi.org\/10.1203\/PDR.0b013e3181b1bd4a","journal-title":"Pediatr Res"},{"key":"4652_CR55","unstructured":"Alexion. Highlights of prescribing information (2019) https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf. Accessed 4\/2\/20"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04652-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T23:33:46Z","timestamp":1623454426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4652"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04652-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"29 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}